An interventional study of Short animated storytelling video in Colorectal Cancer Screening, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Stanford University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Colorectal Neoplasms by Stanford University — 3 open to participants now, 3 under way, none of them phase 3. Colorectal Neoplasms · Stanford University.
Among the 13 studies in Colorectal Neoplasms by Stanford University, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 13th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →3 of the 13 studies in Colorectal Neoplasms by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 10 interventional studies, 9 across the 2 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
1 of the studies in Colorectal Neoplasms by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07522177Stanford UniversityAnimated Storytelling to Promote Colorectal Cancer Screening | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Colorectal Neoplasms by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This online randomized controlled trial will evaluate whether a short animated storytelling video increases behavioral expectation to obtain colorectal cancer screening among screening-eligible U.S. adults who report not yet having completed screening. Participants will be recruited via Prolific and randomized in Stanford Qualtrics to view either a brief animated video or a time-neutral informational text. Outcomes will be assessed immediately after exposure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants view a brief animated storytelling video about colorectal cancer screening and colonoscopy.
Behavioral: Short animated storytelling video
Participants complete surveys only and receive no intervention.
A brief animated storytelling video about colorectal cancer screening and colonoscopy.
Change from baseline in behavioral expectation (simple and next-step) to obtain colorectal cancer screening, as measured by a 7-item visual analogue scale.
Participant self-reports their likelihood of discussing, scheduling, or obtaining colorectal cancer screening after exposure to assigned study material. Total scores range from 0-70 with higher scores indicating greater behavioral expectation (Item 7 is reverse scored).
Time frame: Baseline, immediately post-intervention exposure (up to 24 hours)
Change from baseline in knowledge about colorectal cancer screening and colonoscopy, as measured by a 5-item knowledge questionnaire.
Self-reported knowledge regarding colorectal cancer screening and the preventive role of colonoscopy, including detection and removal of pre-cancerous polyps. Response options are true/false/not sure, with 1 point per correct answer and 0 points for incorrect or "not sure". Total scores range from 0-5, with higher scores indicating higher knowledge.
Time frame: Baseline, immediately post-intervention exposure (up to 24 hours)
Change from baseline in perceptions and beliefs about colonoscopy, as measured by a 13-item scale.
Self-reported perceptions an beliefs about colonoscopy include perceived susceptibility, perceived severity, perceived benefits and perceived barriers. Responses will be compared on a Likert scale that ranges from 1-5 (Strongly disagree / Disagree / Neither / Agree / Strongly agree), where higher scores indicate more positive perceptions and beliefs, with the perceived barriers section reverse scored.
Time frame: Baseline, immediately post-intervention exposure (up to 24 hours)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 1 month is below that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.